Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease

被引：6

作者：

Katagishi, Daiki ^{[1
]}

Yasuda, Daisuke ^{[1
]}

Takahashi, Kyoko ^{[2
]}

Nakamura, Shigeo ^{[2
]}

Mashino, Tadahiko ^{[1
]}

Ohe, Tomoyuki ^{[1
]}

机构：

[1] Keio Univ, Fac Pharm, Dept Pharmaceut Sci, 1-5-30 Shibakoen,Minato Ku, Tokyo, Japan

[2] Nippon Med Sch, Dept Chem, 1-7-1 Kyonan Cho,Musashino, Tokyo, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2023年 / 80卷

关键词：

Fullerene; COVID-19; SARS-CoV-2; Main protease; REVERSE TRANSCRIPTASE INHIBITION; C-60; POLYMERASE;

D O I：

10.1016/j.bmcl.2022.129121

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

COVID-19 is an ongoing worldwide pandemic. Even today, there is a need for the development of effective therapeutic agents. SARS-CoV-2 is known as the causative virus of COVID-19, and its main protease is one of the enzymes essential for its growth and is considered a drug discovery target. In this study, we evaluated the inhibitory activities of a variety of fullerene derivatives, including newly synthesized derivatives, against the main protease of SARS-CoV-2. As a result, the malonic acid-type fullerene derivatives showed the strongest inhibitory activity.

引用

页数：5

共 50 条

[1] Allosteric inhibitors of the main protease of SARS-CoV-2
Samrat, Subodh Kumar
Xu, Jimin
Xie, Xuping
Gianti, Eleonora
Chen, Haiying
Zou, Jing
Pattis, Jason G.
Elokely, Khaled
Lee, Hyun
Li, Zhong
Klein, Michael L.
Shi, Pei-Yong
Zhou, Jia
Li, Hongmin
ANTIVIRAL RESEARCH, 2022, 205
[2] Developing inhibitors of the SARS-CoV-2 main protease
Seitz, Christian
Markota, Vedran
Sztain-Pedone, Terra
Esler, Morgan
Moghadasi, Arad
Kennelly, Samantha
Demir, Ozlem
Aihara, Hideki
Harki, Daniel A.
Harris, Reuben
McCammon, J. Andrew
Amaro, Rommie E.
BIOPHYSICAL JOURNAL, 2022, 121 (03) : 192A - 192A
[3] Potential SARS-CoV-2 main protease inhibitors
Banerjee, Riddhidev
Perera, Lalith
Tillekeratne, L. M. Viranga
DRUG DISCOVERY TODAY, 2021, 26 (03) : 804 - 816
[4] On the origins of SARS-CoV-2 main protease inhibitors
Janin, Yves L.
RSC MEDICINAL CHEMISTRY, 2024, 15 (01): : 81 - 118
[5] Peptidomimetic inhibitors of SARS-COV-2 main protease
Angeles Bonache, Ma.
Algar, Sergio
Medina, Jessy
Diaz-Agustin, Aitor
Bueno, Paula
Castro, Victoria
Fabrega, Montserrat
Coll, Miquel
Garaigorta, Urtzi
Gastaminza, Pablo
Martin Martinez, Mercedes
Gonzalez-Muniz, Rosario
JOURNAL OF PEPTIDE SCIENCE, 2024, 30
[6] Perspectives on SARS-CoV-2 Main Protease Inhibitors
Gao, Kaifu
Wang, Rui
Chen, Jiahui
Tepe, Jetze J.
Huang, Faqing
Wei, Guo-Wei
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (23) : 16922 - 16955
[7] Discovery of novel inhibitors of SARS-CoV-2 main protease
Zheng, Lei
Chen, Yanmei
Bao, Jingxiao
He, Liping
Dong, Suzhen
Qi, Yifei
Zhang, John Z. H.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (23): : 12526 - 12534
[8] Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors
Huff, Sarah
Kummetha, Indrasena Reddy
Tiwari, Shashi Kant
Huante, Matthew B.
Clark, Alex E.
Wang, Shaobo
Bray, William
Smith, Davey
Carlin, Aaron F.
Endsley, Mark
Rana, Tariq M.
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (04) : 2866 - 2879
[9] Potent and biostable inhibitors of the main protease of SARS-CoV-2
Tsuji, Kohei
Ishii, Takahiro
Kobayakawa, Takuya
Higashi-Kuwata, Nobuyo
Azuma, Chika
Nakayama, Miyuki
Onishi, Takato
Nakano, Hiroki
Wada, Naoya
Hori, Miki
Shinohara, Kouki
Miura, Yutaro
Kawada, Takuma
Hayashi, Hironori
Hattori, Shin-ichiro
Bulut, Haydar
Das, Debananda
Takamune, Nobutoki
Kishimoto, Naoki
Saruwatari, Junji
Okamura, Tadashi
Nakano, Kenta
Misumi, Shogo
Mitsuya, Hiroaki
Tamamura, Hirokazu
ISCIENCE, 2022, 25 (11)
[10] Biochemical screening for SARS-CoV-2 main protease inhibitors
Coelho, Camila
Gallo, Gloria
Campos, Claudia B.
Hardy, Leon
Wurtele, Martin
PLOS ONE, 2020, 15 (10):

← 1 2 3 4 5 →